Kura Oncology’s tipifarnib Fast Track’d for T-cell lymphomas

The FDA has designated Kura Oncology’s (NASDAQ:KURA) lead drug tipifarnib for Fast Track review for the treatment of adults with relapsed or refractory angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma and nodal peripheral T-cell lymphoma with T follicular helper phenotype.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

Tipifarnib is inhibits an enzyme called farnesyltransferase which plays a key role in cell cycle progression. Since cancer is defined as unregulated cell proliferation, inhibiting the enzyme would theoretically inhibit cancer progression.

Shares up 10% premarket on light volume.

https://seekingalpha.com/news/3548008-kura-oncologys-tipifarnib-fast-trackd-for-t-cell-lymphomas